Hims & Hers Health (HIMS) Insider David Wells Buys 3,656 Shares

David Wells Increases Hims & Hers Health Position

David Wells acquired 3,656 shares of Hims & Hers Health, Inc. (NYSE: HIMS) on June 11, 2026. This transaction was disclosed in a recent filing and contributes to a busy period of trading for the company's leadership. While the filing did not list a specific purchase price or total dollar value for this specific trade, it serves as a record of his increased ownership in the San Francisco-based health company.

This buy was part of a broader trend of insider moves at Hims & Hers Health in June. On the same day, Delos Cosgrove also acquired 3,656 shares. Just a few days later, on June 15, 2026, CTO Mohamed Elshenawy added 282,597 shares to his holdings. These acquisitions provide a contrast to recent sales by other executives, including Chief Policy Officer Deborah Autor, who sold 15,396 shares at $30.17 each on June 15.

Hims & Hers Health Stock Performance

On Monday, shares of Hims & Hers Health were trading at $26.82. The stock has experienced a wide range of movement over the past year, hitting a low of $13.74 and reaching as high as $57.45. The current price sits just under the 50-day moving average of $29.40, which is a common technical measure used to track short-term price trends. The stock's beta of 2.43 indicates that it often moves much more sharply than the overall market.

Recent Financial Results

Hims & Hers Health generated $2.58 billion in revenue according to its latest financial reporting. The company is growing quickly, with revenue up 38.2% compared to the prior period. However, the business is not yet profitable, reporting a negative net margin of 5.5% and a return on equity of negative 32.0%. Because it isn't profitable, the company does not have a standard P/E ratio, though it carries a forward P/E of 39.85 based on future earnings estimates. The next earnings report is expected on November 9, 2026.

Insider Buying and Selling at Hims & Hers Health, Inc.

The month of June saw a flurry of activity from the Hims & Hers leadership team. In addition to the purchases by Wells and Elshenawy, Chief Legal Officer Soleil Boughton disposed of 42,261 shares on June 15, 2026. Later, on October 14, 2026, Boughton sold another 3,461 shares at a price of $29.06 each, totaling roughly $100,576. That October sale was made through a Rule 10b5-1 plan, which allows insiders to set up a pre-determined schedule for trading their shares.

Analysts Set New Price Targets

Wall Street firms have been active in updating their outlooks for Hims & Hers Health. On August 11, 2026, Needham maintained a Buy rating and raised its price target to $42.00. On the same day, Morgan Stanley kept an Equal-Weight rating but lifted its target from $21.00 to $28.00. More recently, on August 24, 2026, Truist Securities maintained a Hold rating while bumping its price target to $32.00. Barclays also weighed in on August 21, 2026, keeping an Overweight rating but trimming its target to $35.00. The general consensus among 13 analysts is a Hold, with an average price target of $31.15.

About Hims & Hers Health, Inc.

Hims & Hers Health operates a digital platform that connects people with doctors and provides access to various health products. They focus on areas like hair care, skincare, mental health, and weight loss, selling both prescription and over-the-counter items. The company has expanded its reach beyond the U.S. into several European markets and Canada.

Outlook for Investors

Investors should keep an eye on the upcoming earnings announcement in November to see if the company's strong revenue growth begins to translate into profitability. The recent insider buys suggest some leaders are comfortable increasing their stakes, even as others sell under automated plans. It is important to remember that SEC filings and insider reports are backward-looking and show transactions that occurred on specific dates in the past.